Navigation Links
Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
Date:4/14/2009

Expects to qualify for 180 days of sole marketing exclusivity

PITTSBURGH, April 14 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Hoffmann-La Roche Inc. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Capecitabine Tablets, 150 mg and 500 mg, the generic version of Xeloda(R) Tablets, a chemotherapy treatment for breast and colorectal cancer.

Mylan believes it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for the product and expects to qualify for 180 days of sole marketing exclusivity once final FDA approval is obtained. Hoffmann-La Roche filed a lawsuit April 8 in the U.S. District Court for the District of New Jersey alleging infringement of U.S. Patent No. 5,472,949.

Xeloda Tablets, 150 mg and 500 mg, had approximately $447 million in sales for the 12 months ending Dec. 31, 2008, according to IMS Health. Currently, Mylan has 117 ANDAs pending FDA approval, 33 of which are potential first-to-file opportunities.

This press release includes statements that constitute "forward-looking statements," including with regard to the expected first-to-file status and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to de
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
2. Mylan Announces Clarinex(R) Settlement Agreement
3. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
4. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
5. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
6. Mylan Announces Transition of Chief Financial Officer
7. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
8. Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
9. Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... potential for doctors to measure damaging "brain tsunamis" ... moved a step closer to reality, thanks to ... Neuroscience Institute. , The research team, led by ... department of neurosurgery at the UC College of ... spread through an injured brain like tsunami wavescan ...
(Date:9/30/2014)... Sleep apnea is a potential health risk for millions of ... behind the disorder: a "fat" tongue. "This is the ... the tongue of obese patients with obstructive sleep apnea," study ... at the University of Pennsylvania Medical Center, said in a ... findings Oct. 1. Sleep apnea is a common disorder ...
(Date:9/30/2014)... Autism is no stranger to the children of ... is access to clinical services, including reliable diagnosis and ... example, validated for use in Swahili, a major language ... researchers at Brown University and the University of Georgia ... implemented at two sites in the country and found ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... Dynamic health trends, changing consumer ... the Bread Production industry over the past five ... their consumption of a variety of industry goods ... the market for white loaf bread and other ... introducing more nutritious products to attract health-conscious consumers, ...
Breaking Medicine News(10 mins):Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... often forces older adults to give up things ... the ability to exercise and participate in physical ... for Eldercare and Rehabilitation Technology (CERT) are working ... developing and evaluating motion-capture technology that monitors the ...
... than placebo, study finds , , TUESDAY, June 10 (HealthDay News) ... disorder (ADHD) in children, a new study finds. , ... of the American Medical Association , the study compared St. ... 17 and found the herb wasn,t any more effective than ...
... June 10 Sen. Olympia Snowe,(R-ME), member of ... -- S.3101 -- that includes pharmacy-related provisions to ... claims and delay the,implementation of Medicaid reimbursement cuts ... owner of Waltz Pharmacy Inc. in,Camden, ME and ...
... Sen. Gordon Smith,(R-OR), member of the ... includes pharmacy-related provisions to provide prompt,payment of ... delay the,implementation of Medicaid reimbursement cuts for ... National Community Pharmacists,Association (NCPA) past president from ...
... NEW YORK, June 10 Ask any entertainment or ... it,s at. And, while watching,your favorite TV show in ... technology just might., (See video from Siemens ... Biograph HD PET-CT system from Siemens is the world,s ...
... SAN DIEGO and MCLEAN, Va., June 10 SAIC, Inc.,(NYSE: ... William Blair Annual,Growth Stock Conference in Chicago on June 18, ... at 3:10 p.m. Central., A live audio webcast of ... site ( http://investors.saic.com ) and an audio,replay of the event ...
Cached Medicine News:Health News:MU researchers enhancing motion-capture technology to benefit older adults 2Health News:St. John's Wort Doesn't Work for ADHD 2Health News:St. John's Wort Doesn't Work for ADHD 3Health News:Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2Health News:Oregon Community Pharmacy Owner Thanks Sen. Smith for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2Health News:SAIC to Webcast Presentation at William Blair Growth Stock Conference 2
(Date:9/30/2014)... Group finds that the Asia Pacific dental ... , India , Japan ... implant procedure volumes will grow as physicians are increasingly trained on ... findings from Decision Resources Group,s coverage of the Asia ... implant penetration: Penetration of dental implants among the Asia ...
(Date:9/30/2014)... , Sept. 30, 2014 A study using ... offered a new look at the composition of carotid ... physicians understand and treat the disease, a leading cause ... Baptist Health Lexington between September 2010 and May 2012, ... Journal of the American College of Cardiology (JACC) ...
(Date:9/30/2014)... Sept. 30, 2014 BioStructures, LLC has ... Association of Tissue Banks (AATB), it was announced ... Officer. Accreditation follows an intensive nine-month ... trained AATB inspector.  It establishes that the level ... facility meets or exceeds the standards set by ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2
... Biopure Corporation,(Nasdaq: BPUR ) today ... II coronary,revascularization trial have been published in ... "Proof-of-concept trial to,evaluate haemoglobin based oxygen therapeutics ... and haemodynamic,results." The manuscript was authored by ...
... RIDGEFIELD, Conn., May 14 Results of the ... -- the,world,s largest clinical research study for secondary ... European Stroke Conference in Nice,France. In the study, ... similar (9.0% and 8.8%, respectively; HR 1.01, 95% ...
Cached Medicine Technology:Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 2Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 3PRoFESS(R) Results Announced at XVII European Stroke Conference 2PRoFESS(R) Results Announced at XVII European Stroke Conference 3PRoFESS(R) Results Announced at XVII European Stroke Conference 4PRoFESS(R) Results Announced at XVII European Stroke Conference 5
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
The Horizontal-Vertical (H/V) lumbar valve system is the only differential pressure valve for lumbo-peritoneal shunting, which addresses orthostatic overdrainage....
10 overall length 4.5 from bend 250 mm. 90...
Wilson pituitary forcep, flattened tip, 3 mm bite, 145 mm effective....
Medicine Products: